NEW YORK (GenomeWeb News) — George Mason University will use an Aushon Biosystems 2470 arrayer to study targeted cancer treatments, the company said today.
George Mason has installed the 2470 in a CAP-CLIA laboratory that focuses on clinical trials for cancer treatments based on protein expression profiles.
Financial terms of the agreement were not released.